로딩 중…
지수 로딩 중…
Crinetics Pharmaceuticals, Inc.
CRNX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$83.76+0.29%
2026-08-03
Financials
Valuation Metrics
Crinetics Pharmaceuticals, Inc.'s Market Cap is $8.83B. At end of 2025 it was $4.38B. Ranked #1008 of 3,111 in US market (top 32%), #324 of 1,445 on NASDAQ (top 22%), #50 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.83B | US#1,008/3,111 Sec#50/269 |
| Revenue | $18M | US#2,917/3,111 Sec#178/269 |
| Net Income | $-496M | US—/3,111 Sec—/269 |
| Total Assets | $1.40B | US#2,284/3,111 Sec#73/269 |
| Net Assets | $1.28B | US#1,596/3,111 Sec#51/269 |
| Value | ||
| P/B | 6.90x | US#2,416/3,111 Sec#172/269 |
| P/S | 488.77x | US#2,943/3,111 Sec#195/269 |
| FCF Yield | -4.75% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -38.76% | US#2,694/3,111 Sec#153/269 |
| ROA | -35.42% | US#2,918/3,111 Sec#181/269 |
| Op. Margin | -3020.32% | US#2,946/3,111 Sec#186/269 |
| Revenue Growth | 2873.41% | US#14/3,111 Sec#6/269 |
| Financial Health | ||
| Debt Ratio | 9.42% | US#101/3,111 Sec#46/269 |
| Total Debt | $48M | US#2,588/3,111 Sec#150/269 |
| FCF | $-420M | US#2,832/3,111 Sec#257/269 |
| Cash | $114M | US#2,144/3,111 Sec#168/269 |
| Current Ratio | 18.60x | US#128/3,111 Sec#37/269 |
| Performance | ||
| 1Y Return | 200.86% | US#102/3,111 Sec#34/269 |
| 1M Return | 98.34% | US#2/3,111 Sec#1/269 |
| From 52W High | -0.29% | US#28/3,111 Sec#7/269 |
| 1Y MDD | -42.21% | US#2,054/3,111 Sec#151/269 |
| Trading | ||
| Volume | 1,296,504 shares | US#907/3,111 Sec#78/269 |
| Trading Value | $109M | US#654/3,111 Sec#34/269 |
| Per Share | ||
| EPS | $-4.95 | US—/3,111 Sec—/269 |
| BPS | $10.55 | US#1,749/3,111 Sec#60/269 |